{"id":"W4402938149","doi":"10.1177/17588359241277656","title":"Safety of dostarlimab in combination with chemotherapy in patients with primary advanced or recurrent endometrial cancer in a phase III, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université Laval; McGill University Health Centre","funders":"Eisai; Clovis Oncology; Incyte; Novocure; Regeneron Pharmaceuticals; Seagen; Gilead Sciences; Genentech; Mersana Therapeutics; AstraZeneca; Pfizer","keywords":"Medicine; Placebo; Adverse effect; Common Terminology Criteria for Adverse Events; Internal medicine; Endometrial cancer; Randomized controlled trial; Population; Carboplatin; Phases of clinical research; Chemotherapy; Oncology; Surgery; Cancer; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002475868,0.0004594821,0.003608475,0.001275782,0.00002523993,0.000009583699,0.0002394933,0.0003554998,0.0009854379],"category_scores_gemma":[0.0008342499,0.0002630296,0.0001769438,0.002713722,0.000508372,0.000278543,0.00004118902,0.001002284,0.000001884917],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002014942,"about_ca_system_score_gemma":0.001691413,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001991227,"about_ca_topic_score_gemma":0.002351913,"domain_scores_codex":[0.9944746,0.0009864501,0.001975303,0.0007077704,0.001222344,0.0006334629],"domain_scores_gemma":[0.9937876,0.005199616,0.000445297,0.0002537109,0.0001116332,0.000202089],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5623986,0.00522412,0.001264633,0.0001342647,0.0002100541,0.0001697719,0.0005370014,0.000046932,0.000007302435,0.00008991497,9.452976e-7,0.4299164],"study_design_scores_gemma":[0.973422,0.01938529,0.001446699,0.001619869,0.000225895,0.000006871623,0.0001312559,0.0006606193,0.00004444228,0.0005237248,0.002260922,0.0002724247],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9583752,0.02038426,0.0006682164,0.002402721,0.001477796,0.01534351,0.00003086244,0.00005535264,0.00126209],"genre_scores_gemma":[0.9776575,0.01740946,0.0004656772,0.0007948513,0.0001975597,0.003282963,0.00007784426,0.00005212825,0.00006202421],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.429644,"threshold_uncertainty_score":0.9999822,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01383054762002973,"score_gpt":0.3580351310890937,"score_spread":0.344204583469064,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}